Geriatric Medicine Market Analysis By Therapeutic Category (Analgesics, Antihypertensives, Statins, Antidiabetics, Proton Pump Inhibitor, Anticoagulant, Antipsychotic, Antidepressant), by Therapeutic Condition (Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, Respiratory) And Segment Forecasts To 2024

Table of Contents

Chapter 1 Methodology and Scope
                     1.1 Research Methodology
                     1.2 Research Scope & Assumptions
                     1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Geriatric Medicine Industry Outlook
                     3.1 Market segmentation
                     3.2 Geriatric Medicine Market dynamics
                     3.3 Market driver analysis
                     3.4 Market restraint analysis
                     3.5 Key Opportunities Prioritized
                     3.6 Industry analysis - Porter’s
                     3.7 Geriatric Medicine Market PESTEL Analysis
Chapter 4 Geriatric Medicine Therapeutics Outlook
                     4.1 Geriatric Medicine market share by therapeutics, 2015 & 2024
                     4.2 Analgesics
                        4.2.1 Analgesics market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.3 Antihypertensive
                        4.3.1 Antihypertensive market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.4 Statins
                        4.4.1 Statins market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.5 Antidiabetic
                        4.5.1 Antidiabetic market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.6 PPI
                        4.6.1 PPI market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.7 Anticoagulant
                        4.7.1 Anticoagulant market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.8 Antipsychotic
                        4.8.1 Antipsychotic market estimates and forecasts, 2013 - 2024 (USD Billion)
                     4.9 Others
                        4.9.1 Others market estimates and forecasts, 2013 - 2024 (USD Billion)
Chapter 5 Geriatric Medicine Condition Outlook
                     5.1 Geriatric Medicine Market share by condition, 2015 & 2024
                     5.2 Cardiovascular
                        5.2.1 Cardiovascular market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.3 Arthritis
                        5.3.1 Arthritis market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.4 Neurological
                        5.4.1 Neurological market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.5 Cancer
                        5.5.1 Cancer market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.6 Osteoporosis
                        5.6.1 Osteoporosis market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.7 Respiratory
                        5.7.1 Respiratory market estimates and forecasts, 2013 - 2024 (USD Billion)
                     5.8 Others
                        5.8.1 Others market estimates and forecasts, 2013 - 2024 (USD Billion)
Chapter 6 Geriatric Medicine Regional Outlook
                     6.1 Geriatric Medicine Market share, by region, 2015 & 2024
                     6.2 North America
                        6.2.1 Geriatric Medicine Market estimates and forecasts, by therapeutics, 2013 - 2024 (USD Billion)
                              6.2.1.1 U.S. market estimates and forecasts
                              6.2.1.2 Canada market estimates and forecasts
                        6.2.2 Geriatric Medicine Market estimates and forecasts, by condition, 2013 - 2024 (USD Billion)
                              6.2.2.1 U.S. market estimates and forecasts
                              6.2.2.2 Canada market estimates and forecasts
                     6.3 Europe
                        6.3.1 Geriatric Medicine Market estimates and forecasts, by therapeutics, 2013 - 2024 (USD Billion)
                              6.3.1.1 UK market estimates and forecasts
                              6.3.1.2 Germany market estimates and forecasts
                        6.3.2 Geriatric Medicine Market estimates and forecasts, by condition, 2013 - 2024 (USD Billion)
                              6.3.2.1 UK market estimates and forecasts
                              6.3.2.2 Germany market estimates and forecasts
                     6.4 Asia Pacific
                        6.4.1 Geriatric Medicine Market estimates and forecasts, by therapeutics, 2013 - 2024 (USD Billion)
                              6.4.1.1 Japan market estimates and forecasts
                              6.4.1.2 China market estimates and forecasts
                        6.4.2 Geriatric Medicine Market estimates and forecasts, by condition, 2013 - 2024 (USD Billion)
                              6.4.2.1 Japan market estimates and forecasts
                              6.4.2.2 China market estimates and forecasts
                     6.5 Latin America
                        6.5.1 Geriatric Medicine Market estimates and forecasts, by therapeutics, 2013 - 2024 (USD Billion)
                              6.5.1.1 Brazil market estimates and forecasts
                              6.5.1.2 Mexico market estimates and forecasts
                        6.5.2 Geriatric Medicine Market estimates and forecasts, by condition, 2013 - 2024 (USD Billion)
                              6.5.2.1 Brazil market estimates and forecasts
                              6.5.2.2 Mexico market estimates and forecasts
                     6.6 MEA
                        6.6.1 Geriatric Medicine Market estimates and forecasts, by therapeutics, 2013 - 2024 (USD Billion)
                              6.6.1.1 South Africa market estimates and forecasts
                        6.6.2 Geriatric Medicine Market estimates and forecasts, by condition, 2013 - 2024 (USD Billion)
                              6.6.2.1 South Africa market estimates and forecasts
Chapter 7 Competitive Landscape
                     7.1 GlaxoSmithKline Plc.
                        7.1.1 Company Overview
                        7.1.2 Financial Performance
                        7.1.3 Product Benchmarking
                        7.1.4 Strategic Initiatives
                     7.2 Abbott Laboratories, Inc.
                        7.2.1 Company Overview
                        7.2.2 Financial Performance
                        7.2.3 Product Benchmarking
                        7.2.4 Strategic Initiatives
                     7.3 Boehringer Ingelheim GmbH
                        7.3.1 Company Overview
                        7.3.2 Financial Performance
                        7.3.3 Product Benchmarking
                        7.3.4 Strategic Initiatives
                     7.4 AstraZeneca plc
                        7.4.1 Company Overview
                        7.4.2 Financial Performance
                        7.4.3 Product Benchmarking
                        7.4.4 Strategic Initiatives
                     7.5 Bristol-Myers Squibb Company
                        7.5.1 Company Overview
                        7.5.2 Financial Performance
                        7.5.3 Product Benchmarking
                        7.5.4 Strategic Initiatives
                     7.6 Eli Lilly and Company
                        7.6.1 Company Overview
                        7.6.2 Financial Performance
                        7.6.3 Product Benchmarking
                        7.6.4 Strategic Initiatives
                     7.7 Merck & Company Inc.
                        7.7.1 Company Overview
                        7.7.2 Financial Performance
                        7.7.3 Product Benchmarking
                        7.7.4 Strategic Initiatives
                     7.8 Novartis AG
                        7.8.1 Company Overview
                        7.8.2 Financial Performance
                        7.8.3 Product Benchmarking
                        7.8.4 Strategic Initiatives
                     7.9 Pfizer, Inc.
                        7.9.1 Company Overview
                        7.9.2 Financial Performance
                        7.9.3 Product Benchmarking
                        7.9.4 Strategic Initiatives
                     7.10 Sanofi S.A.
                        7.10.1 Company Overview
                        7.10.2 Financial Performance
                        7.10.3 Product Benchmarking
                        7.10.4 Strategic Initiatives

List of Tables

TABLE 1 Geriatric Medicine - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Geriatric Medicine market, by therapeutics, 2013 - 2024 (USD million)
TABLE 3 Geriatric Medicine market, by condition, 2013 - 2024 (USD million)
TABLE 4 Geriatric Medicine therapeutics market, by region, 2013 - 2024 (USD million)
TABLE 5 Geriatric Medicine therapeutics - Key market driver analysis
TABLE 6 Geriatric Medicine therapeutics- Key market restraint analysis
TABLE 7 North America Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD million)
TABLE 8 North America Geriatric Medicine revenue, by condition, 2013 - 2024 (USD Billion)
TABLE 9 U.S.Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 10 U.S.Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 11 Canada Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 12 Canada Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 13 Europe Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 14 Europe Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 15 Germany Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 16 Germany Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 17 UK Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 18 UK Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 19 Asia Pacific Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 20 Asia Pacific Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 21 Japan Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 22 JapanGeriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 23 China Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 24 China Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 25 Latin America Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 26 Latin America Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 27 Brazil Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 28 Brazil Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 29 Mexico Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 30 Mexico Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 32 MEA Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 32 MEA Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 33 South Africa Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)
TABLE 34 South Africa Geriatric Medicine revenue, by therapeutics, 2013 - 2024 (USD Billion)

List of Figures

FIG. 1 Geriatric medicine: Market Segmentation
FIG. 2 Geriatric Medicine Market Revenue, 2013 - 2024 (USD Billion)
FIG. 3 Geriatric Medicine Market Dynamics
FIG. 4 Key Opportunities Prioritized
FIG. 5 Geriatric Medicine - Porter’s Analysis
FIG. 6 Geriatric Medicine Market - PESTEL Analysis
FIG. 7 Geriatric Medicine revenue share by therapeutics, 2015 & 2024
FIG. 8 Analgesics revenue, 2013 - 2024 (USD Billion)
FIG. 9 Antihypertensive revenue, 2013 - 2024 (USD Billion)
FIG. 10 Statins revenue, 2013 - 2024 (USD Billion)
FIG. 11 Antidiabetics revenue, 2013 - 2024 (USD Billion)
FIG. 12 PPI revenue, 2013 - 2024 (USD Billion)
FIG. 13 Anticoagulant revenue, 2013 - 2024 (USD Billion)
FIG. 14 Antipsychotic revenue, 2013 - 2024 (USD Billion)
FIG. 15 Others revenue, 2013 - 2024 (USD Billion)
FIG. 16 Geriatric Medicine revenue share by condition, 2015 & 2024
FIG. 17 Cardiovascular, 2013 - 2024 (USD Billion)
FIG. 18 Female population revenue, 2013 - 2024 (USD Billion)
FIG. 19 Arthritis revenue, 2013 - 2024 (USD Billion)
FIG. 20 Neurological revenue, 2013 - 2024 (USD Billion)
FIG. 21 Cancer revenue, 2013 - 2024 (USD Billion)
FIG. 22 Osteoporosis revenue, 2013 - 2024 (USD Billion)
FIG. 23 Respiratory revenue, 2013 - 2024 (USD Billion)
FIG. 24 Others revenue, 2013 - 2024 (USD Billion)
FIG. 25 Geriatric Medicine revenue share by region, 2015 & 2024
FIG. 26 North America Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 27 U.S.Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 28 Canada Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 29 Europe Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 30 Germany Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 31 UK Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 32 Asia Pacific Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 33 Japan Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 34 China Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 35 Latin America Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 36 Brazil Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 37 MexicoGeriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 38 MEA Geriatric Medicine revenue, 2013 - 2024 (USD million)
FIG. 39 South Africa Geriatric Medicine revenue, 2013 - 2024 (USD million)